SOLICITATION NOTICE
B -- Sample labeling, quality control, C014 hybridization, array scans, data extraction, and segmentation analysis on DNA samples extracted from blood of subjects in melanoma- prone families
- Notice Date
- 8/3/2009
- Notice Type
- Presolicitation
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-90159-AV
- Archive Date
- 8/28/2009
- Point of Contact
- Ashley L. Virts,
- E-Mail Address
-
virtsa@mail.nih.gov
(virtsa@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Division of Epidemiology and Genetics (DCEG), Genetics Epidemiology Branch (GEB) plans to procure on a sole source basis, with Roche Diagnostics Corporation; 9115 Hague Rd.; Indianapolis, IN 46250-0414 for services regarding sample labeling, quality control, C014 hybridization, array scans, data extraction, and segmentation analysis on DNA samples extracted from blood of subjects in melanoma- prone families. The services herein are being procured in accordance with the simplified acquisition procedures authorized by FAR Part 13.106-(b) (1). The North American Industry Classification System Code is 621511 the business size standard is 500 employees. The NCI Division of Cancer Epidemiology and Genetics (DCEG), Genetics Epidemiology Branch (GEB) is currently investigating the relation of the CDNK2A gene and its relation as a high-risk melanoma susceptibility gene as identified to date. Although germline CDKN2A mutations are associated with high risk of cutaneous malignant melanoma (CMM), the penetration of this gene is incomplete and varies by age and geographic location. Further, phenotypic manifestations, such as age at diagnosis, presence/number of dyspiastic nevi (DN), number of melanomas, and co-segregation of pancreatic cancer, vary significantly among mutation carriers even within a single family. The period of performance shall be 6 months from the date of award. The Contractor will compare the copy number changes among mutation carriers to those identified among CMM cases and unaffected family members in CMM-prone families without known mutations. Specifically, the lab will perform studies of C011 on whole-genome arrays CHOI 8 Cal 3x720K WO axon-focused to identify copy number changes that segregate with disease traits in CMM families with CDKN2A mutations. More specifically, genetic DNA including blood samples of 120 subjects from 25 families with CDKN2A mutations to be analyzed for arrayCOH to identify disease-related CNVs. Roche Diagnostics Corporation offers the highest resolution array CGH platfoini on the market for analysis of DNA copy number. Unique features of Roche Diagnostic’s arrays include ultra¬high density and long oligonucleotide probes that provide superior performance and data quality. The tiling-path designs provide comprehensive coverage of both genic and intergenic, regions and are not limited to loci represented by singular nucleopeptide (SNP) arrays. These unique features allow ultra-high resolution detection of small deletions and amplifications as well as breakpoint mapping to gene-level resolution, even in complex regions such as segmental duplication loci. The enhanced sensitivity of long oligonucleotide probes enables better signal-to-noise ratios compared to short probes. Long probes also provide a greater specificity and tolerance for mismatches to detect copy number changes in polymorphic regions of the genome. Roche Diagnostics possesses the unique array platform which specifically fits the study design necessary to complete the objectives in this procurement. For these reasons, including the quality products and proprietary data, Roche Diagnostics is the only source known to the NCI to provide the GEB with the necessary supplies and support to complete the studies outlined in this acquisition. This is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the researcher to determine if the party can meet this requirement. One (1) original and one (1) copy of the capability statement must be received in the contracting office by 11:00 a.m. ET on August 13, 2009. All questions must be in writing and can be faxed to 301-402-4513 or sent via email to Ashley Virts: virtsa@mail.nih.gov. It is the vendor’s responsibility to ensure questions have been received. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractor must have valid, updated registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Application (ORCA). Please reference NCI-90159-AV on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-90159-AV/listing.html)
- Record
- SN01897040-W 20090805/090803235554-8286724c1312b585f40cc5db83d548e7 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |